2017_SBRT_Course Book

DEGRO AG Stereotaxie Project: TOaSST Register Study of concomitant use of SRT and targeted drugs Study design: After SRT: • Patient, tumor, treatment characteristics 3 months: • Acute toxicity

12 months: • Late toxicity • OS, LC, DFS

07.09.17 ESTRO SBRT COURSE 2017 - Matthias Guckenberger

45

/

Discontinuation of TKI

Ø Minimize procedures with risk of discontinuation of systemic Tx Disease flare: rapid disease progression in patients with TKI resistance after discontinuation of systemic treatment MSKCC experience on disease flare: N=61 NSCLC with mEGFR and TKI treatment Resistance development TKI discontinuation N=14 ( 23% ) Disease flare: hospitalization or death Median 8 days (3-21) Chaft Cancer Res 2011

07.09.17 ESTRO SBRT COURSE 2017 - Matthias Guckenberger

46

/